Aptinyx (NASDAQ:APTX) versus Global Blood Therapeutics (NASDAQ:GBT) Head-To-Head Comparison
Aptinyx (NASDAQ:APTX) and Global Blood Therapeutics (NASDAQ:GBT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.
This table compares Aptinyx and Global Blood Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Blood Therapeutics||N/A||-52.25%||-39.47%|
59.3% of Aptinyx shares are held by institutional investors. 8.6% of Aptinyx shares are held by insiders. Comparatively, 4.2% of Global Blood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Aptinyx and Global Blood Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aptinyx||$3.67 million||42.87||-$57.41 million||($1.71)||-1.96|
|Global Blood Therapeutics||$2.11 million||1,597.13||-$266.77 million||($4.71)||-11.66|
Aptinyx has higher revenue and earnings than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Aptinyx, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Aptinyx has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Global Blood Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.
This is a breakdown of current recommendations for Aptinyx and Global Blood Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Blood Therapeutics||0||4||18||0||2.82|
Aptinyx presently has a consensus target price of $11.67, indicating a potential upside of 248.26%. Global Blood Therapeutics has a consensus target price of $106.71, indicating a potential upside of 94.31%. Given Aptinyx’s stronger consensus rating and higher probable upside, research analysts plainly believe Aptinyx is more favorable than Global Blood Therapeutics.
Aptinyx beats Global Blood Therapeutics on 9 of the 14 factors compared between the two stocks.
Aptinyx Company Profile
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.